Advanced search
Publication Cover
Pharmacogenomics Volume 10, 2009 - Issue 11
Submit an article Journal homepage
622
Views
0
CrossRef citations to date
0
Altmetric
Review

Host Genetic Determinants of Spontaneous Hepatitis C Clearance

Andri Rauch1 University Clinic of Infectious Diseases, University Hospital Bern & University of Bern, Inselspital PKT2B, 3010Bern, Switzerland. Correspondence[email protected]
View further author information
,
Silvana Gaudieri2 Royal Perth Hospital and Murdoch University, Perth, Australia;3 University of Western Australia, Perth, AustraliaView further author information
,
Chloe Thio4 Johns Hopkins University, MD, USAView further author information
&
Pierre-Yves Bochud5 University Hospital & University of Lausanne, Lausanne, SwitzerlandView further author information
Pages 1819-1837 | Published online: 05 Nov 2009

Bibliography

  • Seeff LB , HollingerFB, AlterHJ et al.: Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study.Hepatology33(2) , 455–463 (2001).
  • Davila JA , MorganRO, ShaibY, McGlynnKA, El Serag HB: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology127(5) , 1372–1380 (2004).
  • Williams R : Global challenges in liver disease.Hepatology44(3) , 521–526 (2006).
  • Thomas DL , AstemborskiJ, RaiRM et al.: The natural history of hepatitis C virus infection: host, viral, and environmental factors.JAMA284(4) , 450–456 (2000).
  • Falck-Ytter Y , KaleH, MullenKD, SarbahSA, SorescuL, McCulloughAJ: Surprisingly small effect of antiviral treatment in patients with hepatitis C.Ann. Intern. Med.136(4) , 288–292 (2002).
  • Fleming CA , CravenDE, ThorntonD, TumiltyS, NunesD: Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.Clin. Infect. Dis.36(1) , 97–100 (2003).
  • Rauch A , EggerM, ReichenJ, FurrerH: Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-a plus ribavirin.J. Acquir. Immune Defic. Syndr.38(2) , 238–240 (2005).
  • Dore GJ , FreemanAJ, LawM, KaldorJM: Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings.Antivir. Ther.8(5) , 365–372 (2003).
  • Tanaka Y , HanadaK, MizokamiM et al.: Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades.Proc. Natl Acad. Sci. USA99(24) , 15584–15589 (2002).
  • Kenny-Walsh E : Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.N. Engl. J. Med.340(16) , 1228–1233 (1999).
  • Muller R : The natural history of hepatitis C: clinical experiences.J. Hepatol.24(Suppl. 2) , 52–54 (1996).
  • Yeo AE , GhanyM, Conry-CantilenaC et al.: Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers.J. Viral Hepat.8(4) , 256–263 (2001).
  • Watanabe H , SaitoT, ShinzawaH et al.: Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study.J. Med. Virol.71(1) , 56–61 (2003).
  • Dalgard O : Follow-up studies of treatment for hepatitis C virus infection among injection drug users.Clin. Infect. Dis.40(Suppl. 5) , S336–S338 (2005).
  • Yokosuka O , KojimaH, ImazekiF et al.: Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: analysis of HCV RNA in 320 patients who were followed for more than 3 years.J. Hepatol.31(3) , 394–399 (1999).
  • Klenerman P , HillA: T cells and viral persistence: lessons from diverse infections.Nat. Immunol.6(9) , 873–879 (2005).
  • Klenerman P , LucasM, BarnesE, HarcourtG: Immunity to hepatitis C virus: stunned but not defeated.Microbes Infect.4(1) , 57–65 (2002).
  • Bowen DG , WalkerCM: Adaptive immune responses in acute and chronic hepatitis C virus infection.Nature436(7053) , 946–952 (2005).
  • Hoofnagle JH : Course and outcome of hepatitis C.Hepatology36(5 Suppl. 1) , S21–S29 (2002).
  • Thio CL : Host genetic factors and antiviral immune responses to hepatitis C virus.Clin. Liver Dis.12(3) , 713–726 (2008).
  • Asselah T , BiecheI, ParadisV, BedossaP, VidaudM, MarcellinP: Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C.Semin. Liver Dis.27(1) , 13–27 (2007).
  • Kanto T , HayashiN: Innate immunity in hepatitis C virus infection: interplay among dendritic cells, natural killer cells and natural killer T cells.Hepatol. Res.37(Suppl. 3) , S319–S326 (2007).
  • Gale M Jr, Foy EM: Evasion of intracellular host defence by hepatitis C virus. Nature436(7053) , 939–945 (2005).
  • Szabo G , ChangS, DolganiucA: Altered innate immunity in chronic hepatitis C infection: cause or effect?Hepatology46(4) , 1279–1290 (2007).
  • Dustin LB , RiceCM: Flying under the radar: the immunobiology of hepatitis C.Annu. Rev. Immunol.25 , 71–99 (2007).
  • Ebihara T , ShingaiM, MatsumotoM, WakitaT, SeyaT: Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells.Hepatology48(1) , 48–58 (2008).
  • Benedict CA , WareCF: RIGing a virus trap.Nat. Med.11(9) , 929–930 (2005).
  • Garcia-Sastre A , BironCA: Type 1 interferons and the virus–host relationship: a lesson in detente.Science312(5775) , 879–882 (2006).
  • Sadler AJ , WilliamsBR: Interferon-inducible antiviral effectors.Nat. Rev. Immunol.8(7) , 559–568 (2008).
  • Foy E , LiK, WangC et al.: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease.Science300(5622) , 1145–1148 (2003).
  • Knapp S , YeeLJ, FrodshamAJ et al.: Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.Genes Immun.4(6) , 411–419 (2003).
  • Wietzke-Braun P , MaouziAB, ManhardtLB, BickebollerH, RamadoriG, MihmS: Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.Eur. J. Gastroenterol. Hepatol.18(9) , 991–997 (2006).
  • Thomas DL , ThioCL, MartinMP et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.Nature461(7265) , 798–801 (2009).
  • Schott E , WittH, NeumannK et al.: Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy.J. Viral Hepat.15(1) , 71–78 (2008).
  • Bochud PY , HersbergerM, TaffeP et al.: Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection.AIDS21(4) , 441–446 (2007).
  • Bochud PY , MagaretAS, KoelleDM, AderemA, WaldA: Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection.J. Infect. Dis.196(4) , 505–509 (2007).
  • Bochud PY , HawnTR, SiddiquiMR et al.: Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy.J. Infect. Dis.197(2) , 253–261 (2008).
  • Bochud PY , HawnTR, AderemA: Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling.J. Immunol.170(7) , 3451–3454 (2003).
  • Bochud PY , ChienJW, MarrKA et al.: Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.N. Engl. J. Med.359(17) , 1766–1777 (2008).
  • Kaslow RA , DorakMT, TangJJ: Is protection in HIV infection due to Bw4 or not to Bw4?Lancet Infect. Dis.1(4) , 221–222 (2001).
  • Khakoo SI , ThioCL, MartinMP et al.: HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection.Science305(5685) , 872–874 (2004).
  • Rauch A , LairdR, McKinnonE et al.: Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection.Tissue Antigens69(Suppl. 1) , 237–240 (2007).
  • Romero V , AzocarJ, ZunigaJ et al.: Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in hepatitis C virus infection outcome.Mol. Immunol.45(9) , 2429–2436 (2008).
  • Zuniga J , RomeroV, AzocarJ et al.: Protective KIR-HLA interactions for HCV infection in intravenous drug users.Mol. Immunol.46(13) , 2723–2727 (2009).
  • Montes-Cano MA , Caro-OleasJL, Romero-GomezM et al.: HLA-Cand KIR genes in hepatitis C virus infection.Hum. Immunol.66(11) , 1106–1109 (2005).
  • Gaudieri S , NolanD, McKinnonE, WittCS, MallalS, ChristiansenFT: Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses.Mol. Immunol.42(4) , 557–560 (2005).
  • Orland JR , WrightTL, CooperS: Acute hepatitis C.Hepatology33(2) , 321–327 (2001).
  • Farci P , AlterHJ, WongDC et al.: Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization.Proc. Natl Acad. Sci. USA91(16) , 7792–7796 (1994).
  • Day CL , LauerGM, RobbinsGK et al.: Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection.J. Virol.76(24) , 12584–12595 (2002).
  • Gruener NH , LechnerF, JungMC et al.: Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.J. Virol.75(12) , 5550–5558 (2001).
  • Lauer GM , BarnesE, LucasM et al.: High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection.Gastroenterology127(3) , 924–936 (2004).
  • Missale G , BertoniR, LamonacaV et al.: Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.J. Clin. Invest.98(3) , 706–714 (1996).
  • Takaki A , WieseM, MaertensG et al.: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.Nat. Med.6(5) , 578–582 (2000).
  • Thimme R , OldachD, ChangKM, SteigerC, RaySC, ChisariFV: Determinants of viral clearance and persistence during acute hepatitis C virus infection.J. Exp. Med.194(10) , 1395–1406 (2001).
  • Wertheimer AM , MinerC, LewinsohnDM, SasakiAW, KaufmanE, RosenHR: Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection.Hepatology37(3) , 577–589 (2003).
  • Lucas M , Vargas-CueroAL, LauerGM et al.: Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells.J. Immunol.172(3) , 1744–1753 (2004).
  • Wedemeyer H , HeXS, NascimbeniM et al.: Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.J. Immunol.169(6) , 3447–3458 (2002).
  • Cox AL , MosbrugerT, LauerGM, PardollD, ThomasDL, RaySC: Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.Hepatology42(1) , 104–112 (2005).
  • Thimme R , BukhJ, SpangenbergHC et al.: Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.Proc. Natl Acad. Sci. USA99(24) , 15661–15668 (2002).
  • Rehermann B , NascimbeniM: Immunology of hepatitis B virus and hepatitis C virus infection.Nat. Rev. Immunol.5(3) , 215–229 (2005).
  • Graham CS , CurryM, HeQ et al.: Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV.Hepatology40(1) , 125–132 (2004).
  • Bowen DG , WalkerCM: Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man.J. Exp. Med.201(11) , 1709–1714 (2005).
  • Zimmermann M , FlechsigC, La Monica N, Tripodi M, Adler G, Dikopoulos N: Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes. J. Hepatol.48(1) , 51–60 (2008).
  • Carrington M , O‘BrienSJ: The influence of HLA genotype on AIDS.Annu. Rev. Med.54 , 535–551 (2003).
  • Yee LJ : Host genetic determinants in hepatitis C virus infection.Genes Immun.5(4) , 237–245 (2004).
  • Neumann-Haefelin C , ThimmeR: Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection.Genes Immun.8(3) , 181–192 (2007).
  • Singh R , KaulR, KaulA, KhanK: A comparative review of HLA associations with hepatitis B and C viral infections across global populations.World J. Gastroenterol.13(12) , 1770–1787 (2007).
  • Thio CL , GaoX, GoedertJJ, VlahovD et al.: HLA-Cw*04 and hepatitis C virus persistence.J. Virol.76(10) , 4792–4797 (2002).
  • Migueles SA , LaboricoAC, ImamichiH et al.: The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.J. Virol.77(12) , 6889–6898 (2003).
  • Fellay J , ShiannaKV, GeD et al.: A whole-genome association study of major determinants for host control of HIV-1.Science317(5840) , 944–947 (2007).
  • Gaudieri S , DeSantisD, McKinnonE et al.: Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression.Genes Immun.6(8) , 683–690 (2005).
  • Chuang WC , SarkodieF, BrownCJ et al.: Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population.J. Med. Virol.79(6) , 724–733 (2007).
  • Hraber P , KuikenC, YusimK: Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection.Hepatology46(6) , 1713–1721 (2007).
  • McKiernan SM , HaganR, CurryM et al.: Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source.Hepatology40(1) , 108–114 (2004).
  • Kiepiela P , LeslieAJ, HoneyborneI et al.: Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.Nature432(7018) , 769–775 (2004).
  • Neumann-Haefelin C , McKiernanS, WardS et al.: Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution.Hepatology43(3) , 563–572 (2006).
  • Dazert E , Neumann-HaefelinC, BressanelliS et al.: Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response.J. Clin. Invest.9(2) , 376–386 (2008).
  • Rauch A , JamesI, PfafferottK et al.: Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure.Hepatology50(4) , 1017–1029 (2009).
  • Zavaglia C , MartinettiM, SiliniE et al.: Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C.J. Hepatol.28(1) , 1–7 (1998).
  • Zavaglia C , BortolonC, FerrioliG et al.: HLA typing in chronic type B, D and C hepatitis.J. Hepatol.24(6) , 658–665 (1996).
  • Thio CL , ThomasDL, GoedertJJ et al.: Racial differences in HLA class II associations with hepatitis C virus outcomes.J. Infect. Dis.184(1) , 16–21 (2001).
  • Wang JH , ZhengX, KeX et al.: Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection.Virol. J.6 , 46 (2009).
  • Carrington M , NelsonGW, MartinMP et al.: HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.Science283(5408) , 1748–1752 (1999).
  • Grakoui A , ShoukryNH, WoollardDJ et al.: HCV persistence and immune evasion in the absence of memory T cell help.Science302(5645) , 659–662 (2003).
  • Dawkins R , LeelayuwatC, GaudieriS et al.: Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease.Immunol. Rev.167 , 275–304 (1999).
  • Mallal S , NolanD, WittC et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.Lancet359(9308) , 727–732 (2002).
  • Martin AM , NolanD, GaudieriS et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.Proc. Natl Acad. Sci. USA101(12) , 4180–4185 (2004).
  • Degli-Esposti MA , AndreasA, ChristiansenFT, SchalkeB, AlbertE, DawkinsRL: An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes.Immunogenetics35(6) , 355–364 (1992).
  • Mangia A , SantoroR, PiattelliM et al.: IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection.Cytokine25(3) , 103–109 (2004).
  • Knapp S , HennigBJ, FrodshamAJ et al.: Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection.Immunogenetics55(6) , 362–369 (2003).
  • Paladino N , FainboimH, TheilerG et al.: Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism.J. Virol.80(18) , 9144–9150 (2006).
  • Vidigal PG , GermerJJ, ZeinNN: Polymorphisms in the interleukin-10, tumor necrosis factor-α, and transforming growth factor-β1 genes in chronic hepatitis C patients treated with interferon and ribavirin.J. Hepatol.36(2) , 271–277 (2002).
  • Minton EJ , SmillieD, SmithP et al.: Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1, -6, or -10 genes.Hum. Immunol.66(2) , 127–132 (2005).
  • Oleksyk TK , ThioCL, TrueloveAL et al.: Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance.Genes Immun.6(4) , 347–357 (2005).
  • Barrett S , CollinsM, KennyC, RyanE, KeaneCO, CroweJ: Polymorphisms in tumour necrosis factor-α, transforming growth factor-β, interleukin-10, interleukin-6, interferon-γ, and outcome of hepatitis C virus infection.J. Med. Virol.71(2) , 212–218 (2003).
  • Constantini PK , Wawrzynowicz-SyczewskaM, ClareM et al.: Interleukin-1, interleukin-10 and tumour necrosis factor-α gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to α-interferon therapy.Liver22(5) , 404–412 (2002).
  • Hennig BJ , FrodshamAJ, HellierS et al.: Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection.Liver Int.27(8) , 1134–1143 (2007).
  • Trinchieri G : Interleukin-12 and the regulation of innate resistance and adaptive immunity.Nat. Rev. Immunol.3(2) , 133–146 (2003).
  • Houldsworth A , MetznerM, RossolS et al.: Polymorphisms in the IL-12B gene and outcome of HCV infection.J. Interferon Cytokine Res.25(5) , 271–276 (2005).
  • Yin LM , ZhuWF, WeiL et al.: Association of interleukin-12 p40 gene 3´-untranslated region polymorphism and outcome of HCV infection.World J. Gastroenterol.10(16) , 2330–2333 (2004).
  • Mueller T , Mas-MarquesA, SarrazinC et al.: Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.J. Hepatol.41(4) , 652–658 (2004).
  • An P , ThioCL, KirkGD, DonfieldS, GoedertJJ, WinklerCA: Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance.J. Infect. Dis.198(8) , 1159–1165 (2008).
  • Koziel MJ , WongDK, DudleyD, HoughtonM, WalkerBD: Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons.J. Infect. Dis.176(4) , 859–866 (1997).
  • Huang Y , YangH, BorgBB et al.: A functional SNP of interferon-γ gene is important for interferon-α-induced and spontaneous recovery from hepatitis C virus infection.Proc. Natl Acad. Sci. USA104(3) , 985–990 (2007).
  • Lio D , CarusoC, Di Stefano R et al.: IL-10 and TNF-α polymorphisms and the recovery from HCV infection. Hum. Immunol.64(7) , 674–680 (2003).
  • Thio CL , GoedertJJ, MosbrugerT et al.: An analysis of tumor necrosis factor α gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection.Genes Immun.5(4) , 294–300 (2004).
  • Kimura T , SaitoT, YoshimuraM et al.: Association of transforming growth factor-β 1 functional polymorphisms with natural clearance of hepatitis C virus.J. Infect. Dis.193(10) , 1371–1374 (2006).
  • Rudd CE : The reverse stop-signal model for CTLA4 function.Nat. Rev. Immunol.8(2) , 153–160 (2008).
  • Schott E , WittH, HinrichsenH et al.: Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection.J. Hepatol.46(3) , 372–380 (2007).
  • Woitas RP , AhlenstielG, IwanA et al.: Frequency of the HIV-protective CC chemokine receptor 5-δ32/δ32 genotype is increased in hepatitis C.Gastroenterology122(7) , 1721–1728 (2002).
  • Ahlenstiel G , WoitasRP, IwanA et al.: Effects of the CCR5-δ32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.Immunol. Invest.38(1) , 1–13 (2009).
  • Zhang M , GoedertJJ, O‘BrienTR: High frequency of CCR5-δ32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1.Gastroenterology124(3) , 867–868 (2003).
  • Mangia A , SantoroR, D‘AgrumaL, AndriulliA: HCV chronic infection and CCR5-d32/d32.Gastroenterology124(3) , 868–869 (2003).
  • Goulding C , McManusR, MurphyA et al.: The CCR5-δ32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source.Gut54(8) , 1157–1161 (2005).
  • Hellier S , FrodshamAJ, HennigBJ et al.: Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection.Hepatology38(6) , 1468–1476 (2003).
  • Moradpour D , PeninF, RiceCM: Replication of hepatitis C virus.Nat. Rev. Microbiol.5(6) , 453–463 (2007).
  • Hennig BJ , HellierS, FrodshamAJ et al.: Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection.Genes Immun.3(6) , 359–367 (2002).
  • Mas Marques A , MuellerT, WelkeJ et al.: Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection.Infect. Genet. Evol.9(5) , 847–852 (2009).
  • Saito T , JiG, ShinzawaH et al.: Genetic variations in humans associated with differences in the course of hepatitis C.Biochem. Biophys. Res. Commun.317(2) , 335–341 (2004).
  • Micallef JM , KaldorJM, DoreGJ: Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.J. Viral Hepat.13(1) , 34–41 (2006).
  • Alric L , FortM, IzopetJ et al.: Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance.Tissue Antigens56(2) , 154–158 (2000).
  • Villano SA , VlahovD, NelsonKE, CohnS, ThomasDL: Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.Hepatology29(3) , 908–914 (1999).
  • Gerlach JT , DiepolderHM, ZachovalR et al.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.Gastroenterology125(1) , 80–88 (2003).
  • Chung RT , AndersenJ, VolberdingP et al.: Peginterferon α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.N. Engl. J. Med.351(5) , 451–459 (2004).
  • Torriani FJ , Rodriguez-TorresM, RockstrohJK et al.: Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.N. Engl. J. Med.351(5) , 438–450 (2004).
  • Harris HE , EldridgeKP, HarbourS, AlexanderG, TeoCG, RamsayME: Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?J. Viral Hepat.14(3) , 213–220 (2007).
  • Inoue G , HoriikeN, MichitakaK, OnjiM: Hepatitis C virus clearance is prominent in women in an endemic area.J. Gastroenterol. Hepatol.15(9) , 1054–1058 (2000).
  • Hughes AL , NeiM: Maintenance of MHC polymorphism.Nature355(6359) , 402–403 (1992).
  • Timm J , LauerGM, KavanaghDG et al.: CD8 epitope escape and reversion in acute HCV infection.J. Exp. Med.200(12) , 1593–1604 (2004).
  • Goldstein DB : Common genetic variation and human traits.N. Engl. J. Med.360(17) , 1696–1698 (2009).
  • Ge D , FellayJ, ThompsonAJ et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature461(7262) , 399–401 (2009).
  • James I , McKinnonE, GaudieriS, MorahanG: Missingness in the T1DGC MHC fine-mapping SNP data: association with HLA genotype and potential influence on genetic association studies.Diabetes Obes. Metab.11(Suppl. 1) , 101–107 (2009).
  • Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature447(7145) , 661–678 (2007).
  • Spencer CC , SuZ, DonnellyP, MarchiniJ: Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip.PLoS Genet.5(5) , E1000477 (2009).
  • Kumar S , TamuraK, NeiM: MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment.Brief. Bioinform.5(2) , 150–163 (2004).
  • Pandey JP , AstemborskiJ, ThomasDL: Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus.J. Virol.78(9) , 4561–4565 (2004).
  • Pandey JP , NamboodiriAM, LuoY et al.: Genetic markers of IgG influence the outcome of infection with hepatitis C virus.J. Infect. Dis.198(9) , 1334–1336 (2008).
  • Thursz M , YallopR, GoldinR, TrepoC, ThomasHC: Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research.Lancet354(9196) , 2119–2124 (1999).
  • Harris RA , SugimotoK, KaplanDE, IkedaF, KamounM, ChangKM: Human leukocyte antigen Class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African–Americans.Hepatology48(1) , 70–79 (2008).
  • Fanning LJ , LevisJ, Kenny-WalshE, WynneF, WheltonM, ShanahanF: Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen Class II in a homogeneous population.Hepatology31(6) , 1334–1337 (2000).
  • Cramp ME , CarucciP, UnderhillJ, NaoumovNV, WilliamsR, DonaldsonPT: Association between HLA Class II genotype and spontaneous clearance of hepatitis C viraemia.J. Hepatol.29(2) , 207–213 (1998).
  • Minton EJ , SmillieD, NealKR, IrvingWL, UnderwoodJC, JamesV: Association between MHC Class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group.J. Infect. Dis.178(1) , 39–44 (1998).
  • Mangia A , GentileR, CascavillaI et al.: HLA Class II favors clearance of HCV infection and progression of the chronic liver damage.J. Hepatol.30(6) , 984–989 (1999).
  • Congia M , ClementeMG, DessiC et al.: HLA Class II genes in chronic hepatitis C virus-infection and associated immunological disorders.Hepatology24(6) , 1338–1341 (1996).
  • Hohler T , GerkenG, NotghiA et al.: MHC Class II genes influence the susceptibility to chronic active hepatitis C.J. Hepatol.27(2) , 259–264 (1997).
  • Lechmann M , SchneiderEM, GiersG et al.: Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection.Eur. J. Clin. Invest.29(4) , 337–343 (1999).
  • Higashi Y , KamikawajiN, SukoH, AndoM: Analysis of HLA alleles in Japanese patients with cirrhosis due to chronic hepatitis C.J. Gastroenterol. Hepatol.11(3) , 241–246 (1996).
  • Yoon SK , HanJY, PyoCW et al.: Association between human leukocytes antigen alleles and chronic hepatitis C virus infection in the Korean population.Liver Int.25(6) , 1122–1127 (2005).
  • Yenigun A , DurupinarB: Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection.J. Virol.76(4) , 1787–1789 (2002).
  • Ksiaa L , Ayed-JendoubiS, SfarI et al.: Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA Class I and Class II.Viral Immunol.20(2) , 312–319 (2007).
  • Wietzke-Braun P , ManhardtLB, RosenbergerA, UyA, RamadoriG, MihmS: Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates.World J. Gastroenterol.13(31) , 4224–4229 (2007).
  • Zhang M , RosenbergPS, BrownDL et al.: Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia.Blood107(3) , 892–897 (2006).
  • McMahon BJ , HennessyTW, ChristensenC et al.: Epidemiology and risk factors for hepatitis C in Alaska Natives.Hepatology39(2) , 325–332 (2004).
  • Martin-Carbonero L , BarreiroP, Jimenez-GalanG et al.: Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis.J. Viral Hepat.14(6) , 392–395 (2007).
  • Scott JD , McMahonBJ, BrudenD et al.: High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives.Clin. Infect. Dis.42(7) , 945–952 (2006).
  • Marzouk D , SassJ, BakrI et al.: Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt.Gut56(8) , 1105–1110 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.